Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Medtronic PLC    MDT   IE00BTN1Y115

MEDTRONIC PLC (MDT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Medtronic (SWX:MDT) Kicks Off CoreValve Evolut Pro Valve Evaluation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/29/2017 | 12:53pm CEST

Medtronic (SWX:MDT) has announced that it has initiated a post market clinical evaluation of its CoreValve Evolut Pro valve.

The newly announced clinical study of the CoreValve Evolut Pro valve will evaluate its performance based on day to day clinical use. The clinical study will also involve the participation of patients suffering from severe symptomatic aortic stenosis especially those that have a moderate or severe risk of open heart surgery. The evaluation will determine the performance for a duration of five years as it ushers in the future self-expanding TAVI system which recently received approval for use in the U.S and Europe.

“We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve in a study designed to look at the valve’s longer-term real-world performance. The Evolut PRO has shown exceptional results for patients with severe aortic stenosis and we are excited to enroll our first patients into this rigorous study,” stated Dr. Eberhard Grube of Bonn, the co-principal investigator for the clinical study.

The evaluation will be a single-arm study that will involve multiple centers. It also aims to involve 600 patients from 35 European locations in determining the safety of the offering. The CoreValve Evolut Pro consists of an outer wrap that contributes to the surface area between the native aortic annulus and the valve in order to boost the valve sealing performance. The company also revealed that the device features a small form factor to allow for easy delivery through the EnVeo R delivery catheter system.

Dr. Pieter Kappetein, the president of structural heart biz medical affairs at Medtronic pointed a few critical points during a press release. He highlighted that it is his company’s agenda to continue pushing towards meaningful clinical outcomes that are vital for patients as new products enter the global transcatheter valve market. He also added that the outcomes also have to resonate with the physicians and that the company is optimistic that the enhancements featured in the self-expanding Evolut TAVI platform will facilitate better outcomes for patients. Medtronic also hopes that the study will contribute provide evidence of long-term safety and performance.

 

The post Medtronic (SWX:MDT) Kicks Off CoreValve Evolut Pro Valve Evaluation appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDTRONIC PLC
01:50pMEDTRONIC : Wins Expanded Indication for SelectSecure MRI SureScan Pacing Lead f..
AQ
07/13MEDTRONIC : Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
AQ
07/12MEDTRONIC : Wins Expanded Indication for SelectSecure(TM) MRI SureScan(TM) Pacin..
AQ
07/12MEDTRONIC : Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
AQ
07/12MEDTRONIC : First-Year Results from Medtronic and UnitedHealthcare Value-Based R..
AQ
07/11MEDTRONIC : Gets FDA Approval for Less-Invasive Heart Pump Implant Procedure
DJ
07/11MEDTRONIC : Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
AQ
07/11MEDTRONIC : First-Year Results from Medtronic and UnitedHealthcare Value-Based R..
AQ
07/11MEDTRONIC : Launches New Stealthstation™ Technology In Canada For Neurosur..
AQ
07/10UNITEDHEALTH : First-Year Results from Medtronic and UnitedHealthcare Value-Base..
AQ
More news
News from SeekingAlpha
07/12AngioDynamics Slowly Building Confidence In Its Turnaround 
07/11MONTHLY REVIEW OF DIVGRO : June 2018 
07/11FIX YOUR ROOF WHILE THE SUN IS SHINI : The Dividend Aristocrats Are (Sorta) On S.. 
07/09INSPIRE MEDICAL SYSTEMS : Small-Cap Sleeping Beauty 
07/09DIVIDEND SENSEI'S PORTFOLIO UPDATE 4 : 3 Reasons A Perfect Jobs Report Spells Gr.. 
Financials ($)
Sales 2019 30 605 M
EBIT 2019 8 807 M
Net income 2019 5 031 M
Debt 2019 10 521 M
Yield 2019 2,21%
P/E ratio 2019 24,27
P/E ratio 2020 21,29
EV / Sales 2019 4,25x
EV / Sales 2020 3,98x
Capitalization 119 B
Chart MEDTRONIC PLC
Duration : Period :
Medtronic PLC Technical Analysis Chart | MDT | IE00BTN1Y115 | 4-Traders
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,6 $
Spread / Average Target 7,1%
EPS Revisions
Managers
NameTitle
Omar S. Ishrak Chairman & Chief Executive Officer
Mark Ploof Senior Vice President-Global Operations
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC9.42%119 437
BAXTER INTERNATIONAL15.69%40 217
ALIGN TECHNOLOGY63.58%29 130
ZIMMER BIOMET HOLDINGS-4.79%23 354
HOYA CORPORATION10.59%21 544
TERUMO CORP17.84%21 419